Comparative proteomic profiling of Streptococcus agalactiae recovered from the kidneys of diabetic mice

João Matheus Sobral Pena1, Lucas Lima de Oliveira1, Yuri Pereira Souza2

  • 1Laboratório de Biologia Molecular e Fisiologia de Estreptococos, Instituto de Biologia Roberto Alcantara Gomes, Universidade do Estado do Rio de Janeiro (UERJ), Rio de Janeiro,RJ 20550-013, Brazil.

Insights

Hyperglycemia in diabetic mice enhances Streptococcus agalactiae virulence and kidney colonization. This metabolic shift boosts bacterial energy production and virulence factor expression, leading to increased tissue damage.

Area of Science:

  • Microbiology
  • Pathogenesis
  • Diabetic Complications

Background:

  • Streptococcus agalactiae is an opportunistic pathogen causing severe infections, particularly in diabetic individuals.
  • Diabetic individuals exhibit increased susceptibility to S. agalactiae renal infections like pyelonephritis.

Purpose of the Study:

  • To investigate the molecular mechanisms underlying S. agalactiae susceptibility in diabetic conditions.
  • To perform a comparative proteomic analysis of S. agalactiae isolates from diabetic and non-diabetic murine kidneys.

Main Methods:

  • Utilized a streptozotocin-induced diabetic murine model to study S. agalactiae renal infection.
  • Conducted comparative proteomic analysis of S. agalactiae COH1 isolates from diabetic and non-diabetic mouse kidneys.

Main Results:

  • Diabetic mice showed higher bacterial loads and severe renal histopathological damage.
  • Proteomic analysis revealed 82 upregulated and 91 downregulated proteins in S. agalactiae from diabetic kidneys.
  • Upregulated proteins included virulence factors (e.g., serine-rich repeat 2, C5a peptidase) and metabolic enzymes (e.g., glycolysis, PTS system).

Conclusions:

  • Hyperglycemia induces metabolic reprogramming and enhances virulence factor expression in S. agalactiae.
  • These adaptations promote bacterial colonization and tissue damage in diabetic kidneys.
  • Identified potential molecular targets for future therapeutic interventions against S. agalactiae infections in diabetics.